All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

A Phase 3 Open-Label, Randomized, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects

This phase 3 clinical trial is looking at better treatment options for adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). These are slow-growing types of blood cancer that affect white blood cells. Many patients receive targeted medicines known as BTK inhibitors. However, over time, the cancer can become resistant and start growing again. This trial compares a new medicine called rocbrutinib with an existing targeted medicine called pirtobrutinib (Jaypirca). Both drugs are taken as tablets and are designed to block signals that cancer cells need to multiply. Participants will be randomly chosen to receive either rocbrutinib or pirtobrutinib. Doctors will closely track how long the treatment keeps the cancer from growing, monitor overall health, and watch for any side effects. The goal is to discover whether rocbrutinib offers a more effective, safe option for people whose cancer has returned.

At a glance

Status
Authorised
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Newave Pharmaceutical Inc.
Enrolment target
148
Start
20 Oct 2026

What is this study about?

Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are closely related types of blood cancer. They affect white blood cells called lymphocytes, which normally help your body fight off infections. In people with CLL or SLL, the body makes too many abnormal lymphocytes that do not work properly. Over time, these cells can build up in the blood, bone marrow, and lymph nodes.

In recent years, treatments called BTK inhibitors have changed how doctors care for these cancers. These targeted drugs work by blocking a specific protein inside cancer cells, stopping them from growing. However, cancer cells can adapt over time. When a treatment stops working or the cancer returns, doctors call this 'relapsed' or 'refractory' disease. Patients in this situation need new, effective options.

This trial is comparing a new investigational tablet, rocbrutinib, against another targeted tablet called pirtobrutinib. Both medicines are designed to overcome the resistance that can develop after earlier treatments. Researchers want to find out which of these two drugs is better at controlling the cancer and keeping patients well for longer.

Because this is a phase 3 study, it is one of the final stages of research before a new drug can be widely approved. The results will help doctors understand which treatment provides the best balance of cancer control and manageable side effects for people living with these conditions.

Key takeaways

  • A phase 3 study comparing two oral targeted medicines: rocbrutinib and pirtobrutinib.
  • Aimed at adults with CLL or SLL whose cancer has returned after taking an earlier BTK inhibitor.
  • There is no placebo; all participants receive an active treatment.
  • The study looks at how long each drug keeps the cancer under control and monitors side effects.
  • Taking part is voluntary, and you can withdraw at any time.

Who may be eligible?

This trial is open to adults aged 18 and over who have been diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). To be considered, your cancer must have returned or continued to grow after earlier therapy.

Crucially, you must have already received a specific type of targeted medicine known as a covalent BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The trial is designed specifically for people whose cancer did not fully respond to these drugs or started growing again after taking them.

You will also need to meet standard health checks to ensure taking part is safe for you. Your hospital team will review your heart, liver, and kidney function, as well as any other medical conditions or treatments you are currently receiving.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have a confirmed diagnosis of chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
  3. My cancer has returned or progressed (relapsed or refractory).
  4. I have previously been treated with a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib).
  5. I am well enough to attend regular hospital appointments and take daily tablets.
Answer every question to see your result.

What does participation involve?

If you decide to join this study, you will be randomly assigned by a computer to receive either rocbrutinib or pirtobrutinib. Neither you nor your doctor can choose which tablet you receive, but you will know which medicine you are taking. Both drugs are taken by mouth at home.

You will need to visit the hospital regularly for check-ups, especially during the first few months. These visits will involve blood tests, physical examinations, heart checks (ECGs), and occasional scans to see how your leukaemia or lymphoma is responding. You will also be asked about any symptoms or side effects you experience.

You can stay on the study medicine for as long as it continues to control your cancer and the side effects remain manageable. After treatment ends, the research team will keep in touch periodically to check on your overall health.

Potential risks and benefits

Taking part in this study may help control your cancer, and it gives you access to a targeted treatment monitored closely by specialist doctors. The knowledge gained may also help future patients with CLL or SLL. However, there is no guarantee that the treatment will work for you. Both study drugs can cause unwanted side effects, which your medical team will explain in detail and monitor carefully. Joining the study is completely your choice. You can decide to leave at any point without it affecting your standard NHS care or your relationship with your healthcare team.

Locations (6)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Poland
  • —
    Unverified
    Germany
  • —
    Unverified
    Spain
  • —
    Unverified
    Czechia
  • —
    Unverified
    Italy
  • —
    Unverified
    France

Common questions

What is the difference between CLL and SLL?

They are essentially the same disease. Doctors call it CLL when the abnormal cells are found mainly in the blood and bone marrow, and SLL when they are mostly found in the lymph nodes.

Will I receive a dummy pill (placebo)?

No. Every participant in this study will receive an active cancer medicine—either rocbrutinib or pirtobrutinib.

How are the medicines taken?

Both rocbrutinib and pirtobrutinib are tablets that you swallow with water at home, following the schedule given by your study nurse.

What happens if my cancer gets worse during the trial?

Your doctor will monitor your scans and blood tests regularly. If the medicine stops working, you will stop taking it and your doctor will discuss other treatment options with you.

Can I leave the study if I change my mind?

Yes. You have the right to withdraw from the trial at any time, for any reason, without giving an explanation and without losing any standard medical care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.